In 1999, Paulo J. Oliveira received his Bachelor of Science from Universidade de Coimbra in Biochemistry. In 2003, he completed his PhD in Cellular Biology from the same University. After completing his doctorate, Paulo Oliveira spent more than three years working at the Medical School of the University of Minnesota, Duluth, USA, where he collaborated with several researchers and contributed to the publication of several peer-reviewed manuscripts. Paulo Oliveira current research interests include the alteration of cardiac mitochondrial function by physical activity and diet, cardiac mitochondrial dysfunction and cell death caused by anti-neoplastic agents, mitochondrial alterations during cancer stem cell differentiation and carcinogenesis or rational designing of mitochondrial-directed agents. Paulo has about 180 peer-reviewed publications and a h-factor of 35 (Web of Science). He is currently one of the most well-known Portuguese researchers in this area, collaborating with several collaborations in Europe, Africa and in the USA. He has also received several prizes from the Portuguese Cardiology Society for his work on cardiac mitochondrial research. Besides research, Paulo Oliveira is often involved in teaching at the Department of Life Sciences, University of Coimbra, as well as in other Universities in Portugal and elsewhere, besides in numerous science communication activities. Of importance, he has maintained a consistent primary role in the organization of national and international scientific meetings, including the International Courses in Toxicology (2005-2010 in Coimbra), 2013 Annual Meeting of the European Society for Clinical Investigation (Albufeira, Portugal) and the 2014 Meeting of the Portuguese Biochemical Society. Since April 2013, Paulo Oliveira is also Vice-President of the European Society for Clinical Investigation.
Paulo Oliveira has also been reviewer for more than 40 different scientific journals and over 10 different funding agencies, including the European Commission (Research Executive Agency) and the Portuguese Foundation for Science and Technology.